SmithKline Beecham's angiotensin II receptor antagonist Teveten(eprosartan) has been launched in its first market, Germany. The drug was approved there earlier this year (Marketletter June 9). Germany is acting as the rapporteur state for European Union approval under the mutual recognition procedure.
The product is available in 300mg and 400mg tablet formulations in three pack sizes; 25, 56 and 98 tablets. The price ranges from 39.99 Deutschemarks (about $21.37) for 28 x 300mg, to 199.93 marks for 98 x 400mg.
Eprosartan is the third drug in this class to reach the market after Merck & Co's Cozaar (losartan) and Novartis' Diovan (valsartan). SB filed an application for the use of Teveten in essential hypertension with the US Food and Drug Administration in October 1996. The drug is also in Phase II trials for the treatment of congestive heart failure and progressive renal disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze